Rheumatoid Arthritis India Drug Forecast and Market Analysis to 2023 Market reports on India presents the latest report on “Rheumatoid Arthritis India Drug Forecast and Market Analysis to 2023” http://www.marketreportsonindia.com/life-sciences-market-research-reports12381/pharmapoint-rheumatoid-arthritis-india-drug-forecast-market-analysis1.html This Report analysis of the impact of key events as well the drivers and restraints affecting the India Rheumatoid arthritis market. 19th Jan 2016 – Navi Mumbai, India: Market reports on India presents the latest report on “Rheumatoid Arthritis India Drug Forecast and Market Analysis to 2023”. This report make more informed business decisions from insightful and in-depth analysis of drug performance. Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch. The drivers of growth in this market include the increasing RA patient population, and economic growth, which has led to increased investment in the national healthcare system. However, Indian physicians' preference for generics and biosimilars, which have been known to launch prior to patent expiry, has limited the growth of branded products. In addition, because intellectual property law is not enforced in India, there is a disincentive for large pharmaceutical companies to launch their products in the country. Scope - Overview of Rheumatoid arthritis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in the India including product description, safety and efficacy profiles as well as a SWOT analysis.
Rheumatoid arthritis india drug forecast and market analysis to 2023
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.